Endoscopic Near Infrared Photoimmunotherapy Using a Fiber Optic Diffuser for Peritoneal Dissemination of Gastric Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Apr 21

PMID 29676827

Citations 27

Authors

Tadanobu Nagaya

Shuhei Okuyama

Fusa Ogata

Yasuhiro Maruoka

Peter L Choyke

Hisataka Kobayashi

Affiliations

Soon will be listed here.

Abstract

Near infrared photoimmunotherapy (NIR-PIT) is a highly selective tumor treatment that employs an antibody-photo-absorber conjugate (APC) which is activated by near infrared light. Here, we describe the efficacy of endoscopic NIR-PIT using the APC trastuzumab-IR700DX (tra-IR700) in the setting of human epidermal growth factor 2 positive (HER2 + ) gastric carcinoma with peritoneal disseminations. In this in vivo study, fluorescence endoscopy showed high tumor accumulation of tra-IR700 within disseminated peritoneal implants. Mice with disseminated peritoneal gastric cancer were separated into 4 groups: (i) control (no treatment); (ii) tra-IR700 i.v. only; (iii) NIR light only; and (iv) endoscopic NIR-PIT. NIR light irradiation was carried out through a fiber optic diffuser under endoscopic guidance. In vivo bioluminescence images showed significantly greater therapeutic effect in the endoscopic NIR-PIT group than that in the control groups (P < .01 vs other control groups). Histological analysis showed diffuse cancer cell death in NIR-PIT-treated tumors. In conclusion, NIR-PIT with NIR light delivered via an endoscopic fiber optic diffuser is a promising method for the treatment of peritoneal dissemination of gastric cancer. Moreover, this technique could be readily used in other types of cancers with peritoneal dissemination provided that suitable antibodies could be found.

Citing Articles

Evaluation of a Novel Lateral Emitting Laser Fiber for Near-Infrared Photoimmunotherapy.

Suzuki M, Kobayashi H, Hanaoka H Cancers (Basel). 2024; 16(14).

PMID: 39061197 PMC: 11274731. DOI: 10.3390/cancers16142558.

Near-infrared photoimmunotherapy targeting PD-L1: Improved efficacy by preconditioning the tumor microenvironment.

Inagaki F, Kano M, Furusawa A, Kato T, Okada R, Fukushima H Cancer Sci. 2024; 115(7):2396-2409.

PMID: 38671582 PMC: 11247602. DOI: 10.1111/cas.16195.

Near-Infrared Photoimmunotherapy Using a Protein Mimetic for EGFR-Positive Salivary Gland Cancer.

Yamaguchi H, Suzuki T, Okada Y, Ono J, Sano H, Banba A Int J Mol Sci. 2024; 25(6).

PMID: 38542206 PMC: 10970010. DOI: 10.3390/ijms25063233.

Tumor Suppression by Anti-Fibroblast Activation Protein Near-Infrared Photoimmunotherapy Targeting Cancer-Associated Fibroblasts.

Glabman R, Olkowski C, Minor H, Bassel L, Kedei N, Choyke P Cancers (Basel). 2024; 16(2).

PMID: 38275890 PMC: 10813865. DOI: 10.3390/cancers16020449.

Endoscopic Diagnosis and Therapy for Epstein-Barr Virus-Associated Gastric Cancer.

Yanai H, Fujiwara J, Toyama E, Okuda H, Miura O, Kaino S Microorganisms. 2023; 11(11).

PMID: 38004633 PMC: 10673609. DOI: 10.3390/microorganisms11112619.

References

Hino H, Murayama Y, Nakanishi M, Inoue K, Nakajima M, Otsuji E . 5-Aminolevulinic acid-mediated photodynamic therapy using light-emitting diodes of different wavelengths in a mouse model of peritoneally disseminated gastric cancer. J Surg Res. 2013; 185(1):119-26. DOI: 10.1016/j.jss.2013.05.048. View

Ishida M, Kagawa S, Shimoyama K, Takehara K, Noma K, Tanabe S . Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer. Mol Cancer Ther. 2016; 15(3):402-11. PMC: 4783182. DOI: 10.1158/1535-7163.MCT-15-0644. View

Kishi K, Yano M, Inoue M, Miyashiro I, Motoori M, Tanaka K . Talaporfin-mediated photodynamic therapy for peritoneal metastasis of gastric cancer in an in vivo mouse model: drug distribution and efficacy studies. Int J Oncol. 2010; 36(2):313-20. View

Nagaya T, Okuyama S, Ogata F, Maruoka Y, Choyke P, Kobayashi H . Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer. Cancer Sci. 2018; 109(6):1902-1908. PMC: 5989863. DOI: 10.1111/cas.13621. View

Hu Y, Masamune K . Flexible laser endoscope for minimally invasive photodynamic diagnosis (PDD) and therapy (PDT) toward efficient tumor removal. Opt Express. 2017; 25(14):16795-16812. DOI: 10.1364/OE.25.016795. View

Nagaya T, Nakamura Y, Sato K, Harada T, Choyke P, Kobayashi H . Near infrared photoimmunotherapy of B-cell lymphoma. Mol Oncol. 2016; 10(9):1404-1414. PMC: 5067212. DOI: 10.1016/j.molonc.2016.07.010. View

Nagaya T, Nakamura Y, Sato K, Harada T, Choyke P, Hodge J . Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody. Oncotarget. 2016; 8(5):8807-8817. PMC: 5341755. DOI: 10.18632/oncotarget.12410. View

Nagaya T, Sato K, Harada T, Nakamura Y, Choyke P, Kobayashi H . Near Infrared Photoimmunotherapy Targeting EGFR Positive Triple Negative Breast Cancer: Optimizing the Conjugate-Light Regimen. PLoS One. 2015; 10(8):e0136829. PMC: 4552472. DOI: 10.1371/journal.pone.0136829. View

Nagaya T, Nakamura Y, Okuyama S, Ogata F, Maruoka Y, Choyke P . Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. Mol Cancer Res. 2017; 15(9):1153-1162. PMC: 5581714. DOI: 10.1158/1541-7786.MCR-17-0164. View

10.

Ogawa M, Tomita Y, Nakamura Y, Lee M, Lee S, Tomita S . Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget. 2017; 8(6):10425-10436. PMC: 5354669. DOI: 10.18632/oncotarget.14425. View

11.

Okuyama S, Nagaya T, Sato K, Ogata F, Maruoka Y, Choyke P . Interstitial near-infrared photoimmunotherapy: effective treatment areas and light doses needed for use with fiber optic diffusers. Oncotarget. 2018; 9(13):11159-11169. PMC: 5834257. DOI: 10.18632/oncotarget.24329. View

12.

DeLaney T, Sindelar W, Tochner Z, Smith P, Friauf W, Thomas G . Phase I study of debulking surgery and photodynamic therapy for disseminated intraperitoneal tumors. Int J Radiat Oncol Biol Phys. 1993; 25(3):445-57. DOI: 10.1016/0360-3016(93)90066-5. View

13.

Nagaya T, Nakamura Y, Sato K, Zhang Y, Ni M, Choyke P . Near infrared photoimmunotherapy with an anti-mesothelin antibody. Oncotarget. 2016; 7(17):23361-9. PMC: 5029632. DOI: 10.18632/oncotarget.8025. View

14.

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

15.

Thomassen I, van Gestel Y, van Ramshorst B, Luyer M, Bosscha K, Nienhuijs S . Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2013; 134(3):622-8. DOI: 10.1002/ijc.28373. View

16.

Nagaya T, Nakamura Y, Okuyama S, Ogata F, Maruoka Y, Choyke P . Syngeneic Mouse Models of Oral Cancer Are Effectively Targeted by Anti-CD44-Based NIR-PIT. Mol Cancer Res. 2017; 15(12):1667-1677. PMC: 5712275. DOI: 10.1158/1541-7786.MCR-17-0333. View

17.

Kobayashi W, Liu Q, Nakagawa H, Sakaki H, Teh B, Matsumiya T . Photodynamic therapy with mono-L-aspartyl chlorin e6 can cause necrosis of squamous cell carcinoma of tongue: experimental study on an animal model of nude mouse. Oral Oncol. 2005; 42(1):46-50. DOI: 10.1016/j.oraloncology.2005.05.009. View

18.

Hu Y, Masamune K . Flexible coaxial laser endoscope with arbitrarily selected spots in endoscopic view for photodynamic tumor therapy. Appl Opt. 2016; 55(30):8433-8440. DOI: 10.1364/AO.55.008433. View

19.

Mitsunaga M, Nakajima T, Sano K, Choyke P, Kobayashi H . Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug Chem. 2012; 23(3):604-9. PMC: 3401044. DOI: 10.1021/bc200648m. View

20.

Mitsunaga M, Ogawa M, Kosaka N, Rosenblum L, Choyke P, Kobayashi H . Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat Med. 2011; 17(12):1685-91. PMC: 3233641. DOI: 10.1038/nm.2554. View